Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tumours, Gynecological Clear all
Terminated Phase 2 Interventional Results available

Trisenox® in Women With Metastatic Endometrial Cancer

NCT01184053
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Arsenic trioxide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Not applicable Interventional

Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers

NCT04626895
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 2, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes

NCT03081455
View directory record Official record
Conditions
Hereditary Cancer
Interventions
Diagnostic Test
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Waterbury, Connecticut • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

NCT02744898
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin AUC, Abraxane
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Phase 4 Interventional

Rectus Sheath Block for Analgesia After Gynecological Laparotomy

NCT06575699
View directory record Official record
Conditions
Gynecologic Surgical Procedures
Interventions
Rectus sheath block, Thoracic Epidural Analgesia, Liposomal bupivacaine, Bupivacaine Hydrochloride, Bupivacaine-Hydromorphone Cassette
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Recruiting Phase 2 Interventional

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

NCT05979610
View directory record Official record
Conditions
Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Reiki therapy
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Not applicable Interventional Results available

Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy

NCT02000908
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
photobiomodulation, Sham treatment, Physiotherapy
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 2, 2026, 8:06 AM EDT
Active, not recruiting Not applicable Interventional

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

NCT05220033
View directory record Official record
Conditions
Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Cervical Cancer, Uterine Cancer
Interventions
Informational intervention, survey administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 2, 2026, 8:06 AM EDT
Completed No phase listed Observational

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

NCT03604653
View directory record Official record
Conditions
Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
HIPEC, Mitomycin c, CDDP 50, CDDP 75, Doxorubicin
Device · Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT02855944
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Chemotherapy, Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 2, 2026, 8:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Perspective of Telemedicine in Gynecology Oncology

NCT04624165
View directory record Official record
Conditions
Oncology
Interventions
Survey
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 2, 2026, 8:06 AM EDT
Completed No phase listed Observational

Assessment of Screening Modalities for Gynecologic Cancers

NCT00879840
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Controls Without Endometrial Cancer, Controls Without Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 120 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 2, 2026, 8:06 AM EDT
Terminated Phase 1 Interventional

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

NCT03277482
View directory record Official record
Conditions
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer, Metastatic Vulvar Cancer, Metastatic Endometrial Cancer, Recurrent Cervical Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Recurrent Endometrial Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 2, 2026, 8:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

NCT04700527
View directory record Official record
Conditions
Toxicity, Radiation Toxicity
Interventions
Short Chain Fatty Acid, Tapioca Flour
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning

NCT02842047
View directory record Official record
Conditions
Stage IV Gastrointestinal Cancer, Advanced Gynecological Cancer
Interventions
Stop, Breathe & Think™, End of Life Planning Videos, Caregiver wellness videos
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 2, 2026, 8:06 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients

NCT07608445
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Educational Intervention, Goal Setting, Interview, Referral, Rehabilitation, Supportive Care, Survey Administration, Tailored Intervention
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Recruiting No phase listed Observational

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

NCT06672497
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Interventions
Not listed
Lead sponsor
University of South Carolina
Other
Eligibility
20 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 2, 2026, 8:06 AM EDT
Active, not recruiting Phase 2 Interventional

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079
View directory record Official record
Conditions
Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
Interventions
Durvalumab, Internal Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers for Gynecologic Cancer

NCT02178462
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Benign Gynecological Disease
Interventions
Not listed
Lead sponsor
Ajinomoto Co., Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 2, 2026, 8:06 AM EDT
Suspended Phase 3 Interventional

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

NCT00865488
View directory record Official record
Conditions
Ovarian Cysts, Endometriosis, Adhesions
Interventions
ADHEXIL
Biological
Lead sponsor
OMRIX Biopharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2009 · Synced Oct 2, 2026, 8:06 AM EDT
Recruiting Phase 2 Interventional

Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer

NCT06855524
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Breast Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Oligo-fucoidan, Placebo Administration, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

NCT03073525
View directory record Official record
Conditions
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Vigil, Atezolizumab
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 2, 2026, 8:06 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions
RMC-6291
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Springdale, Arkansas • Orange, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 2, 2026, 8:06 AM EDT
Completed Not applicable Interventional

Post-Operative Gynecological Oncology App Study

NCT02932098
View directory record Official record
Conditions
Genital Neoplasm, Female
Interventions
Discharge instructions reminders, Prompts to report symptoms via the web-enabled app, Clinical Alerts
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Southaven, Mississippi • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 2, 2026, 8:06 AM EDT